Barroso-García et al. ADA vs IFX vs TCZ in severe ocular Behcets with refractory cystoid macular edema. Remission 76% (ADA), 60% (IFX), 67% (TCZ). @RheumNow #ACR22 Abstr#1564 https://t.co/pRVgIdGAGS https://t.co/gOb5wQ9pHv

• Anti-TNF versus Anti-IL6 Receptor Antagonist Therapy in Severe Ocular Involveme…

Abs 0829 at #ACR22 finds AOSD more commonly affects caucasian females. Also notes abnormal labs include elevated inflammatory markers, leukocytosis, and anemia. @RheumNow https://t.co/1Nr8C5dX3G

• Adult Onset Still's Disease: A Retrospective Study of Objective Manifestat…

VEXAS Abs 0823 #ACR22: Pulmonary disease is common VEXAS, frequently pulmonary infiltrates. It remains unclear if respiratory manifestations are part of the primary disease or a co-existing condition. What are you seeing in clinical practice? @RheumNow https://t.co/VBVKLIrsqq https://t.co/QhxtCdNi5v

• Pulmonary Manifestations in VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammat…

70% of #AOSD pts were females! Large HCA database study - incidence rate - 0.16 - 0.21 per 100,000 (similar to French studies). 24% required ICU level of care, 12% had PNA (fig) Mortality is higher than other cohorts - 3.2% #ACR22 @RheumNow abst#0829 https://t.co/fcFUnExYOE

#ACR22 Abstr#0826 2 years on since FDA approved #Tocilizumab in Adults Onset Still's Disease, real-world data from Japan affirmed its effectiveness and as a steroid-sparring agent @RheumNow https://t.co/jbmhEnGwXO

Kaneko et al. Tocilizumab leads to significantly lower steroid doses in Adult onset Stills Disease @RheumNow #ACR22 Abstr#0826 https://t.co/jc1S6sdfkm https://t.co/z0cHB4wYu6

• Treatment Pattern and Changes in Oral Glucocorticoid Dose After Tocilizumab Tre…

New concept of sJIA to MAS as a continuum on the spectrum of disease severity. Molecular basis via impact of mTORC1 (mechanistic target of rapamycin complex 1) inhibition in Il1rn-/- mice. Looking forward to the full paper. Huang Z Abs004 https://t.co/3OtIp90PnG #ACR22 @RheumNow https://t.co/PPHQj8bYKu

• mTORC1 Drives the Spectrum of Pathology in Systemic JIA and Macrophage Activati…

Germany based 74 pt #FMF prospective non-interventional, multicenter observational study on Canakinumab - RELIANCE Registry 63% in remission in 2 yrs serious adverse drug reactions - 1.56 per 100 patient years @RheumNow #ACR22 abst#0138

#ACR22 Abstr#0127. Cross-sectional study of 59 patients with #SAPHO and Chronic Nonbacterial Osteomyelitis showed that patients had high level of pain and fatigue and low function. Important to assess for these and could be a treatment target @RheumNow https://t.co/451KrlJWZF

mTORC1 may be driver of inflammation that connects the pathogenesis of sJIA and MAS as seen in mouse models. Further evaluation needs to be determined in humans, but interesting nonetheless. Abs 0004 #ACR22 @RheumNow https://t.co/RFokZqFQZp https://t.co/E7yxCPDGCd

• mTORC1 Drives the Spectrum of Pathology in Systemic JIA and Macrophage Activati…